Bioanalytics - Biomolecular

(M0930-06-36) Elements of Robust Modified Oligonucleotide Extraction through SPE

(T0930-06-36) scRNA-seq - A Potential ELISpot Alternative?

(T0930-06-37) Highly Sensitive Analysis Using EVOSEP-LC/MS Assay for Targeted PD-L1 and PD1 Expression Level for Predicting Response to Immune Checkpoint Inhibitors

(T0930-06-38) Quantitative Analysis of GalNAc-siRNA Conjugates in Tissue Homogenate Using Two-Dimensional Liquid Chromatography Coupled with Tandem Mass Spectrometry

(M0930-06-39) Enhanced Pharmacokinetic Bioanalysis of Antibody-Drug Conjugates Using Hybrid Immunoaffinity Capture and Microflow LC-MS/MS

(T0930-06-39) Quantitative Characterization of Oligonucleotide Transport Vehicle (OTV) In Vivo Distribution and Pharmacokinetics using Ultra-sensitive, Plate-Based Bioanalytical Methods

(M0930-06-41) Comparison of Branched DNA (B-DNA) and Polymerase Chain Reaction (RT-qPCR) Method Validation for the Quantification of mRNA Therapeutics in Plasma

(W1030-06-36) Novel Technical Breakthrough: qPCR with Reported LLOQ of 8 Copies / mg DNA in a 20 µL Reaction

(T1030-06-36) Sanger Sequencing of Oligonucleotide Pharmaceuticals

(M1030-06-36) Stabilization of Human Cells for RNA Extraction Using Capillary-Mediated Vitrification Process

(M1030-06-37) Strategies and Case Studies to Develop Ultra-sensitive LC-MS/MS Assays for Quantification of Inhalation Drugs in Human Plasma

(T1030-06-37) Strategies for Measuring Oligonucleotides Using a Fully Automated Microfluidic Immunoassay System

(M1030-06-38) Immunocapture LC-MS/MS Assay for the Biomarker, Troponin Fast (TNNI2) Using a Specific Antibody

(T1030-06-38) Optimizing Flow Cytometric Immune Phenotyping and CAR Persistence Determination to Enable Immune Monitoring of Patients under CAR T Cell Therapy

(W1030-06-38) Use of Human Plasma as a Surrogate Matrix for Quantitation of Modified Protein Therapy across Multiple Tumor Tissues

(W1030-06-39) Comprehensive LC-MS/MS Analysis of VSV-GP Lipidome

(T1030-06-39) Optimal Mobile Phase and Antisense Oligonucleotide Modifications for the Internal Standard in Bioanalysis of Therapeutic Oligonucleotides by Ion-Pair LC-MS/MS

(M1030-06-39) Robust Quantification Method Development for Antisense Oligonucleotide by LC-MS/MS

(T1130-06-36) Method Development of BI-X ADC Gyrolab Assay for the Determination of Anti-BI-X Antibodies

(W1130-06-36) Understanding Synthetic High-Density Lipoprotein Remodeling Ex Vivo Using Human Serum

(W1130-06-37) Validation of an In Vitro Cell-Based Assay for the Detection of Neutralizing Antibodies against Adeno-Associated Virus 9 in Cynomolgus Monkey

(T1130-06-38) Development and Validation of a Novel ECL Method for the Quantitative Detection of Complement C3 in Human Serum

(M1130-06-38) Innate Immune Response Modulating Impurities Assay for Assessing Synthetic Semaglutide and Liraglutide

(W1130-06-39) Bioanalysis of Endonuclease Cas9 in Plasma Conducing to Clarify CRISPR-Cas9-Mediated Genome Engineering Using Immunocapture followed with LC-MS/MS Screener Application

(M1130-06-39) PABE: A Novel Enhanced Drug Tolerant Assay Format to Detect Anti-Drug Antibodies in the Presence of High Concentrations of rhAAT-Fc

(T1130-06-39) Targeted Profiling of Lipid Mediators as Serum Biomarkers of Inflammation in a Case Study

(M1130-06-40) Development and Validation of a Sensitive Hybridization-Electrochemiluminescence (H-ECL) Method for Quantitation of STK-002, an Antisense Oligonucleotide, in Human Serum

(W1130-06-40) Validating Digital Droplet PCR (ddPCR) Assay with Zero-Inflated Poisson Model

(T1230-06-36) Development and Validation of an LC-MS/MS Method for the Quantification of Hydrogen Sulfide in Isolated Tissues from Porcine Eyes

(W1230-06-36) LC-MS/MS Method Development and Validation for Quantitative Analysis of CART Peptides in Cell Culture Supernatant and Human Plasma

(M1230-06-36) Method Development and Validation of a Sensitive and Robust Human Serum PK Immunoassay for a Novel Bispecific Antibody by an Automated Microfluidic System

(M1230-06-37) Development of a Sensitive and Specific Phospho-Tau 217 [Tau (pT217)] Biomarker Assay for Alzheimer’s Disease in Plasma and Serum

(T1230-06-37) Expansion of the Human Immuno-Oncology Assay Portfolio on a Multiplexed Electrochemiluminescence Platform

(W1230-06-37) PD-L1 Gene Expression Quantification in Single Cell on Tissue for Accurately Predicting Response to ICIs

(M1230-06-38) Evaluation of Free vs Total Measurement of Monoclonal Antibody-Based Therapeutics with Low Binding Affinity to Soluble Target

(W1230-06-38) Measuring Free IgE in Low-Affinity Interaction with Omalizumab Using an Automated Microfluidic Immunoassay to Support Pharmacokinetics and Pharmacodynamics Studies

(T1230-06-38) Performance of a Digoxigenin Antibody-Based Electrochemiluminescent Hybridization Assay: A HELISA Alternative for Low Femtomolar Detection of an Antisense Oligonucleotide

(T1230-06-39) Prediction of Hematocrit through Potassium Measurement in Whole Blood Using Volumetric Absorptive Microsampling

(M1330-06-36) Determination of Microdystrophin (h-µD5) via Signature Peptide Analysis in Muscle Tissue by LC-MS/MS

(T1330-06-36) Duplicate-Well vs Single-Well Analysis in Ligand Binding Assays (LBAs): A Retrospective Comparison of Method Validations and Nonclinical Toxicokinetic (TK) Sample Analyses Data

(M1330-06-38) Comparison of Manual and Automated Nucleic Acid Extraction Methods

(T1330-06-38) Rapid Quantitation of Docosahexaenoic Acid and Its Hydroxy Metabolites in Liver Cells Using Differential Mobility Separation (SelexION) Coupled with Liquid Chromatography Tandem Mass Spectrometry

(M1330-06-39) Regulatory Perspective of Considerations in Endogenous Therapeutic Analyte Bioanalysis

(M1330-06-40) A Comprehensive Bioanalytical Strategy of In Vivo Studies for RNAi Therapeutics in Early Discovery

(T1430-06-36) Immunogenicity Assessment: A Comparative Study between a Chemically Labeled and an Enzymatically Biotinylated rAAV9 Vector

(M1430-06-36) Qualification of a Neurology 2-Plex B (Nf-L, GFAP) Quanterix Simoa® Assay Using a Novel Approach

(T1430-06-37) Quantum Electrochemical Spectroscopy (QES): A Novel AI-Driven Spectroscopic Approach to Simplify Bioanalytical Development in the Pharmaceutical and Biotech Industries

(M1430-06-37) Toward Development of a New QCM-D Based Method for Rapid Detection of a Novel Biomarker of Morbidity and Mortality Risk in Sepsis Patients

(T1430-06-38) Content Uniformity, Drug Quantification and Cross-Reactivity Analysis of Protein Loaded PGSU Implants Using Raman Spectroscopy and Reverse-Phase High Performance Liquid Chromatography (RP-HPLC)

(M1430-06-39) A Comprehensive Array of Bioanalytical Assays to Assess the Pharmacokinetic Properties of Antibody-Drug Conjugates In Vivo and In Vitro

(T1430-06-39) A Process of Method Development for Tissue Homogenization and Analysis to Eliminate Binding and Matrix Effects Using Surrogate Matrices

(M1430-06-40) Development of an Ultrasensitive qPCR Method to Identify and Quantify Point Mutation in Circulating Tumor DNA

(T1430-06-40) Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry Method Development and Pharmacokinetics of PTH-IA in Mice

(T1530-06-36) An End-to-End One-Pot Immunoaffinity-LC-MS/MS Assay for Simultaneous Quantitation of Total and Conjugated Antibody Levels of Antibody-Drug Conjugates with Protease-Cleavable Linkers

(T1530-06-38) Out of Endotoxin Box: Rethinking Pyrogens

(T1530-06-39) A Two-Part Method for the Separation and Quantification of Free and Encapsulated ASOs by Hybridization ELISA

(T1530-06-40) Analyzing Insulin Glargine Biosimilars: Stability, Degradation, and Structural Characterization